Phillips Edward, Jones Robin L, Huang Paul, Digklia Antonia
Royal Marsden Hospital, London, United Kingdom.
Royal Marsden Hospital, Division of Clinical Sciences, Institute of Cancer Research, London, United Kingdom.
Front Pharmacol. 2022 Mar 30;13:869754. doi: 10.3389/fphar.2022.869754. eCollection 2022.
Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to dacarbazine. Eribulin appears to be particularly effective for liposarcomas. It has also been shown to be a safe and effective treatment alternative to doxorubicin in patients where doxorubicin is contraindicated. From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.
软组织肉瘤是一组高度异质性的肿瘤，全身治疗选择有限。艾日布林是一种合成的海兔毒素B类似物，是一种有效的有丝分裂抑制剂。一项针对先前接受过治疗的晚期脂肪肉瘤和平滑肌肉瘤的3期试验表明，艾日布林优于达卡巴嗪。艾日布林似乎对脂肪肉瘤特别有效。在多柔比星禁忌的患者中，它也已被证明是一种安全有效的替代多柔比星的治疗方法。从回顾性研究来看，艾日布林在血管肉瘤、多形性肉瘤、滑膜肉瘤、横纹肌肉瘤、血管肉瘤和黏液纤维肉瘤患者中已显示出疗效。未来的发展领域包括脂质体艾日布林，它可能会提高疗效并降低毒性，以及确定反应和耐药的生物标志物，以便更好地选择治疗患者。
